|
COPYRIGHT 2007 Asia Pulse Pty Ltd
(Full text of a statement. Contact details below.)
(BW)(NY-OMRIX)(OMRI) OMRIX Biopharmaceuticals Submits Market Authorization Application (MAA) to European Medicines Agency (EMEA) for Approval to Market Evicel(TM) with General Hemostasis Indication
NEW YORK--(BUSINESS WIRE)--July 30, 2007--OMRIX Biopharmaceuticals, Inc. ("OMRIX" or the "Company") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets protein-based biosurgery and passive immunotherapy products, announced today that it has submitted a Market Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market EVICEL* Fibrin Sealant (Human), or Evicel, the Company's second generation liquid fibrin sealant, with an expanded indication of General Hemostasis in...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
